title: Dopamine in the management of shock.
abstract: Shock is a syndrome with serious prognostic implications--the harbinger of death. Hypoperfusion of essential organs is common, though total blood flow may be significantly greater than normal. Specific therapy is directed to the specific inciting event--infection, abscess, tamponade, &c. Symptomatic therapy keeps the patient alive until we discover the specific problem or until he recovers spontaneously. The intravascular volume must be carefully monitored and corrected, using the pulmonary wedge pressure as the principal guide, and colloid osmotic pressure must be maintained. If the patient does not respond to volume augmentation alone then inotropic drugs may be needed, and of these dopamine is a selective vasodilator which redirects blood flow to the critical organs. The outstanding challenge in shock is the maldistribution of perfusion in the microvasculature. Although this may be ameliorated by the early administration of large doses of glucocorticoids, there is little convincing that these drugs constitute more than supportive therapy. Of greatest importance is reevaluation, reevaluation, and reevaluation. The patient in shock becomes a new patient every five minutes. Drugs that formerly worked, doses previously optimal--these are no guide because the situation changes so rapidly. The principles of management are to monitor vital functions, constantly vary drugs and doses, and continually attempt to put right all the parameters measured. This strategy will be more effective when we know what parameters to measure.
mesh_terms: D001810:Blood Volume / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use*; D006801:Humans; D012039:Regional Blood Flow / Q000187:drug effects; D012769:Shock / Q000188:drug therapy* / Q000503:physiopathology; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D014665:Vasodilator Agents; D004298:Dopamine
references.citation: Circ Res. 1959 Jul;7(4):649-57
references.pmid: 13663218
references.citation: J Appl Physiol. 1951 Aug;4(2):77-101
references.pmid: 14888620
references.citation: Ann Surg. 1967 Apr;165(4):504-17
references.pmid: 6021451
references.citation: Cardiovasc Res. 1968 Oct;2(4):329-37
references.pmid: 5727764
references.citation: J Chronic Dis. 1971 Jun;24(1):61-9
references.pmid: 5568746
references.citation: Circulation. 1975 Sep;52(3):5-9
references.pmid: 1157250
references.citation: Crit Care Med. 1975 Mar-Apr;3(2):51-8
references.pmid: 1157508
references.citation: Am J Physiol. 1975 Dec;229(6):1668-74
references.pmid: 1211500
references.citation: Am J Surg. 1975 Nov;130(5):565-9
references.pmid: 1200270
references.citation: J Surg Res. 1976 Feb;20(2):77-84
references.pmid: 1256047
references.citation: Arch Surg. 1973 May;106(5):630-6
references.pmid: 4701410
references.citation: Crit Care Med. 1973 Mar-Apr;1(2):75-80
references.pmid: 4754223
references.citation: Crit Care Med. 1974 Sep-Oct;2(5):229-34
references.pmid: 4455449
references.citation: Crit Care Med. 1974 Nov-Dec;2(6):317-25
references.pmid: 4448095
references.citation: Crit Care Med. 1974 Nov-Dec;2(6):326-36
references.pmid: 4448096
references.citation: Circulation. 1975 Feb;51(2):350-7
references.pmid: 234302
references.citation: Am J Surg. 1973 Jul;126(1):37-41
references.pmid: 4197529
references.citation: J Trauma. 1975 Jan;15(1):39-41
references.pmid: 1117467
references.citation: Clin Res. 1976 Oct;24(4):258-66
references.pmid: 1024008